Market Signal Briefing

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ANF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.

However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.

New Gold (NGD - Free Report) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank.

Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).

Here are three of the most important factors that make the stock of this gold mining company a great growth pick right now.

Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for New Gold is 29%, investors should actually focus on the projected growth. The company's EPS is expected to grow 177.5% this year, crushing the industry average, which calls for EPS growth of 65.4%.

Cash Flow GrowthCash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.

Right now, year-over-year cash flow growth for New Gold is 41.6%, which is higher than many of its peers. In fact, the rate compares to the industry average of 6%.

While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 15.6% over the past 3-5 years versus the industry average of 15.4%.

Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

There have been upward revisions in current-year earnings estimates for New Gold. The Zacks Consensus Estimate for the current year has surged 11% over the past month.

Bottom LineWhile the overall earnings estimate revisions have made New Gold a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination indicates that New Gold is a potential outperformer and a solid choice for growth investors.

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.

However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects, makes it pretty easy to find cutting-edge growth stocks.

Genpact (G - Free Report) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank.

Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.

Here are three of the most important factors that make the stock of this business process management services provider a great growth pick right now.

Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Genpact is 11.7%, investors should actually focus on the projected growth. The company's EPS is expected to grow 9.8% this year, crushing the industry average, which calls for EPS growth of 9.2%.

Impressive Asset Utilization RatioGrowth investors often overlook asset utilization ratio, also known as sales-to-total-assets (S/TA) ratio, but it is an important feature of a real growth stock. This metric shows how efficiently a firm is utilizing its assets to generate sales.

Right now, Genpact has an S/TA ratio of 0.97, which means that the company gets $0.97 in sales for each dollar in assets. Comparing this to the industry average of 0.93, it can be said that the company is more efficient.

In addition to efficiency in generating sales, sales growth plays an important role. And Genpact looks attractive from a sales growth perspective as well. The company's sales are expected to grow 6% this year versus the industry average of 5.3%.

Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Genpact have been revising upward. The Zacks Consensus Estimate for the current year has surged 2.7% over the past month.

Bottom LineGenpact has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination indicates that Genpact is a potential outperformer and a solid choice for growth investors.

Key Takeaways Agilent's Q4 earnings were in line with estimates and reported 9.4% revenue growth.
Strong LDG and ACG sales drove the top-line, with both segments rising on reported and core bases.
Agilent issued Q1 and full-year 2026 guidance, indicating continued reported and core revenue growth.

Agilent Technologies (A - Free Report) reported fourth-quarter fiscal 2025 earnings of $1.59 per share, which were in line with the Zacks Consensus Estimate. The figure increased 8.9% year over year.

Revenues of $1.86 billion surpassed the Zacks Consensus Estimate by 1.49%. The top line increased 9.4% on a reported basis and 7.2% on a core basis (excluding acquisitions and divestitures) year over year.

Agilent shares are down 1.13% in the pre-market trading.

Agilent’s Q4 Top-Line DetailsThe company operates through three reporting segments—Life Sciences and Diagnostics Markets Group (“LDG”), Agilent CrossLab Group (“ACG”) and Applied Markets Group (“AMG”).

LDG: The segment generated $755 million and accounted for 40.6% of the company’s total revenues. This represented a 15% increase on a reported basis and an 11% rise on a core basis year over year.

ACG: Revenues from the segment were $755 million, accounting for 40.6% of the total revenues. The top line grew 7% on a reported basis and 6% on a core basis year over year.

AMG: Revenues increased 4% year over year to $351 million on a reported and 3% on a core basis, accounting for the remaining 18.9% of the total revenues.

Agilent’s Q4 Operating ResultsFor the fourth quarter of fiscal 2025, the LDG segment’s gross margin contracted 90 basis points (bps) year over year to 52.9%. ACG’s gross margin decreased 140 bps year over year to 54.9%, while AMG’s gross margin declined 40 bps year over year to 54.6%.

Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose to $386 million, marking a 6.6% increase from the prior-year quarter.

As a percentage of revenues, Research and development expenses fell 20 bps year over year to 6.2%, while selling, general and administrative expenses fell 50 bps year over year to 20.7%.

The non-GAAP operating margin of 27.1% for the fiscal fourth quarter contracted 30 bps on a year-over-year basis.

Segment-wise, LDG operating margin increased 130 bps year over year to 22.7%. ACG’s operating margin fell 130 bps year over year to 32.5%. Meanwhile, AMG’s operating margin contracted 70 bps year over year to 24.7%.

A’s Balance Sheet DetailsAs of Oct. 31, 2025, Agilent’s cash and cash equivalents were $1.78 billion, up from $1.54 billion as of July 31, 2025.

The long-term debt was $3.05 billion as of Oct. 31, 2025, compared with $3.35 billion as of July 31, 2025.

Agilent’s Q1 & FY26 GuidanceFor the first quarter of fiscal 2026, Agilent expects revenues in the range of $1.79-$1.82 billion, indicating a rise of 6% to 8% on a reported basis and 4% to 6% on a core basis. Non-GAAP earnings are expected to be between $1.35 per share and $1.38 per share.

For fiscal 2026, Agilent expects revenues between $7.3 billion and $7.4 billion, implying an increase of 5-7% on a reported basis and 4-6% on a core basis. The company expects non-GAAP earnings between $5.86 per share and $6.00 per share.

A’s Zacks Rank & Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).

BioLife Solutions (BLFS - Free Report) , Phibro Animal Health (PAHC - Free Report) and Medtronic (MDT - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector. While BLFS and PAHC sport a Zacks Rank #1 (Strong Buy), MDT carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

BioLife Solutions shares have gained 1.5% in the year-to-date period. The Zacks Consensus Estimate for BioLife Solutions' 2025 earnings is pegged at 7 cents per share, up by a couple of pennies over the past 30 days, suggesting growth of 200% from the year-ago quarter’s reported figure.

Phibro Animal Health shares have surged 105.2% in the year-to-date period. The Zacks Consensus Estimate for Phibro Animal Health’s 2025 earnings is pegged at $2.76 per share, up by 9.09% over the past 30 days, suggesting year-over-year growth of 32.06%.

Medtronic shares have surged 29.2% in the year-to-date period. The Zacks Consensus Estimate for Medtronic's fiscal 2026 earnings is pegged at $5.65 per share, implying a rise of 2.91% from the year-ago quarter’s levels.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

BONK traded near $0.000009655, up 6.08%, extending its multiday rebound. A 3 trillion token volume spike — 85% above average — aligned with the breakout through $0.00001000.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Cardano price has been one of the top laggards during the ongoing crypto market crash. ADA trades at $0.4100, its lowest point in over a year, and 70% below its highest level in December last year. So, will the coin rebound as Charles Hoskinson hints of a surge in its DeFi total value locked?

Will Cardano Price Benefit if TVL Jumps as Hoskinson Expects?
Cardano price has been a top laggard in the crypto industry, partly because many investors see it as a ghost chain. In a recent X post, Nansen’s CEO predicted that it would fall out of the top 20 biggest coins as nobody used it. 

Cardano to Fall Out of Top 20
Indeed, when Cardano’s network suffered a glitch, the trending joke was that no one noticed, as no one uses it. This criticism will likely change soon as the network may see a surge in activity.

In a recent video recording, Charles Hoskinson noted that Cardano’s network will see a surge in activity and total value locked (TVL) soon. He pointed to the upcoming Midnight project, which will be launched in December this year.

According to Hoskinson, the platform has already made major partnerships with some of the biggest developers in the crypto industry. As a result, he expects that these developers will boost the total value locked (TVL) in Midnight and Cardano in extension.

Additionally, Hoskinson has hinted of an upcoming RealFi project that will supercharge the network’s growth. 

His statement came as third-party data shows that Cardano’s network is languishing. The TVL in its network has dived by 36% in the last 30 days to $186 million. In contrast, Monad, which launched its mainnet on Monday, is nearing $100 million in TVL. Cardano has less than $40 million in stablecoin supply and no market share in industries like gaming and RWA. 

Cardano TVL has dived
ADA Price Technical Analysis
The daily chart reveals that the Cardano price has been in a strong downward trend as it continues to underperform other tokens. It has dived below the important support level at $0.5097, where it formed a double-bottom pattern a few months ago. 

Cardano’s Relative Strength Index (RSI) and other top oscillators have continued its downtrend. The RSI has already moved below the oversold level, which is a sign that it may rebound soon. 

Most importantly, it has formed a falling wedge pattern whose two lines are about to converge. Therefore, the most likely ADA price forecast is moderately bullish, with the initial target being the resistance level at $0.5097. 

Cardano Price Chart
On the other hand, a drop below the lower side of the wedge will cancel the bullish outlook. It will bring the target price to $0.2772, its lowest level in August last year. 

TL;DR

Flow Traders’ integration with the Cap protocol shows that a regulated institution is now using onchain financing secured by automated guarantees.
The architecture will combine Cap, EigenLayer, and YieldNest in a programmable system that allocates capital, enforces collateral, and reduces operational risks.
The company will be able to access loans backed by restaked assets.

Flow Traders is taking a decisive step into the institutional onchain credit market. The company, publicly traded on Euronext Amsterdam and one of the largest liquidity providers in the world, is beginning to operate directly with the Cap protocol using EigenLayer infrastructure.

This partnership allows a regulated institution to access decentralized capital in a functional, traceable, and automatically secured manner. It marks a real shift: institutions stop viewing the DeFi ecosystem from the outside and begin using it for concrete financial operations.

Flow Traders Will Be Able to Take Out Loans Backed by Restaked Assets
Flow Traders handles billions of dollars in daily trading volume and is one of the main market makers in ETFs, ETPs, equities, fixed income, commodities, and crypto. Its integration with Cap enables the firm to take out loans backed by restaked assets and deploy them in market-making strategies, similar to how it obtains short-term financing in traditional markets, but with greater transparency, automatic settlement, and lower operational friction.

What Does Each Company Provide?
The architecture is the result of Cap, EigenLayer, YieldNest, and Flow Traders operating together in a single financial cycle without intermediaries. Cap defines how capital moves and how risks are managed through smart contracts. There is no human intervention in execution, collateral control, or repayment, which reduces operational risks and eliminates discretionary interpretation in credit management.

EigenLayer provides the restaking mechanism, where ETH or LST holders delegate their stake to operators. If the operator fails or defaults, the system can apply slashing and automatically enforce collateral. YieldNest acts as the institutional restaker and secures Flow Traders’ activity by delegating OETH while monitoring the process within the EigenLayer framework.

Flow Traders acts as the credit beneficiary and deploys the capital received from Cap into market strategies. Yield for restakers is generated as compensation for assuming onchain credit risk, and the relationship between all participants is governed by programmed rules that define settlements, collateral management, and consequences in the event of default.

This design replaces traditional credit relationships based on bilateral trust with a programmable market governed by executable contracts. The DeFi market already offers competitive capital allocation mechanisms for institutional firms, with lower costs, immediate settlement, and verifiable guarantees.

Cap is positioning itself as a functional bridge between traditional finance and onchain systems, and Flow Traders demonstrates that institutions can already operate with protocols without sacrificing financial discipline, regulatory oversight, or risk control.

XRP traders are once again arguing about upside targets after popular chartist Charting Guy reposted a bullish long-term setup and doubled down on his call that XRP can still reach $8 this cycle. “XRP still going to $8, idc,” he wrote on X in the early hours of Nov. 25, alongside a weekly XRP/USD chart from Bitstamp.

XRP Price Still Has Room To Run
At the time of the screenshot, XRP was trading around $2.25, up roughly 9.8% on the week, with the chart plotting an Elliott Wave structure from early 2023 into a projected peak in 2026. The analysis is built on a dense Fibonacci framework spanning from about $0.25 to a 1.272 extension at $8.29661, which anchors his upside target.

XRP price analysis | Source: X @ChartingGuy
The green wave count shows a classic five-wave impulse. Wave 1 launches from the post-bear-market base into the 0.618 Fibonacci level near $0.915, where the first leg tops out. Wave 2 then retraces for 51 weekly bars (357 days), bottoming just above the 0.382 retracement at $0.41315.

Wave 3 is drawn as a steep rally off that base, blasting through all mid-range Fibonacci bands and extending beyond the 1.0 level at $3.31700. In the replies, one user suggested the spike to around $3.65 had already completed the fifth wave; Charting Guy rejected that outright: “it wasn’t… was very clearly a B wave.”

From that high, the chart records a year-long consolidation labelled as Wave 4, annotated as 50 weekly bars (350 days). Price fluctuates between roughly the mid-$2 area and above $3. The Wave-4 low holds above the 0.786 Fibonacci support at $1.61246, never revisiting the $1 region.

From this consolidation, the projected Wave 5 shoots higher from around the $2–$2.30 zone—where XRP is currently trading—toward the 1.272 extension at $8.29661. The “5” marker sits at this level, and the projection shows only a modest pullback after touching the band, implying that this area is treated as the probable cycle cap.

The Fibonacci grid also frames the current battle zone. XRP’s price is oscillating around the 0.888 level at $2.27404, which lines up almost exactly with the latest weekly close, while the prior wave-3 region around $3.317 remains the next major resistance band on the chart.

Not everyone is convinced. “Could still go under 1.50. Still,” wrote another user. Charting Guy’s response was curt: “no.” That stance matches the technical layout: in his count, the $1.61 area has already printed the Wave-4 low, and the structure does not include another trip below that support.

Others pushed for higher numbers. “Was hoping for $20+,” one follower admitted. “could happen,” the analyst replied—before clarifying to another user that “$20 is not on track but still entirely possible.” His published chart, however, draws no path beyond the $8.29 extension, underlining that mid-single-digit territory remains his primary target for this cycle.

At press time, XRP traded at $2.20.

XRP price, 1-week chart | Source: XRPUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

TL;DR

XRP open interest falls to its lowest in one year.
Most trading liquidity has now moved to Binance.
Negative funding rates signal potential further price declines.

XRP trading loses momentum as open interest falls to a one-year low. The token struggles to find a clear direction, leaving derivative traders on hold for a strong signal.

During the recent drop below $2, XRP lost most of its open interest. The token briefly bounced to around $2.21, recovering from local lows, but trading volumes have diminished over the past months.

XRP Liquidity shifts to Binance
Most liquidity for XRP moved to Binance, which now handles over 7% of its trading. On the exchange, open positions fell from $1.7B to $591M, hitting a recent low of $473M. Both long and short positions declined as traders avoided the choppy market. The lack of directional conviction prevents sustained momentum for derivative activity.

The largest decline in open interest occurred when XRP dropped below $2, and rebuilding positions may take longer. Lower prices combined with low open interest indicate that traders are waiting for clearer signals, while short-term activity fails to support a price recovery.

Indicators point to potential downside
XRP funding rates have often turned negative on certain exchanges, signaling selling pressure and potential further declines. Social media sentiment among retail traders remains mostly bearish, reflecting the aftermath of whale distribution without renewed accumulation by large holders.

XRP’s ETF prospects in 2025 were delayed, with Solana taking the lead in new products. Ripple announced plans for a $1B treasury, although it already holds large reserves of tokens. The XRPL layer liquidity remains limited, capturing only a small share of DeFi activity.

Despite a 21% rise in social media mindshare over recent weeks, XRP remains predominantly bearish until new liquidity sources emerge. Derivative traders continue to monitor the market, awaiting a clear directional signal to reenter positions.

BNB Chain just wrapped two events in Buenos Aires during Devconnect Argentina 2025, targeting early-stage Web3 developers and aimed at expanding the ecosystem.

Summary

The two-day Buenos Aires hackathon began on Nov. 15 with a Demo Night on Nov. 16 aimed at early-stage Web3 developers and ecosystem growth.
Hackathon participants competed across eight categories including AI, DeFi, trading, payments, and wallets, with access to BNB Chain’s $1B Builder Fund.
The events were supported by BNB Chain’s infrastructure stack—BNB Smart Chain, opBNB, and BNB Greenfield—and its security and builder-support programs.

The BNB Hack: Buenos Aires event took place from November 15-16 as part of the global BNB Hack Local Series. The hackathon provided participants access to the company’s $1 billion Builder Fund.

According to a BNB Chain blog:

The Buenos Aires stop of the BNB Chain x YZi Labs Hack Series brought two intense days of building, collaboration, and sharp ideas from across LATAM and the global DevConnect crowd. With 19 submissions, 4 live demos, and a packed venue, the city showed once again why it’s becoming one of the most active blockchain hubs in the region.

Developers competed across eight categories, including artificial intelligence, decentralized finance, trading, payments, and wallets. The competition offered a $160,000 prize pool, up to $50,000 in ecosystem support, and expedited interviews for the Most Valuable Builder program, the statement said.

BNB Chain’s Demo Night on November 16 featured live demonstrations, keynote presentations, and panel discussions designed to connect builders with potential investors and partners, the organization stated.

BNB Chain comprises three components: BNB Smart Chain, opBNB, and BNB Greenfield, which provide blockchain infrastructure for decentralized finance applications, data storage, and developer tools. The network utilizes AvengerDAO and Red Alarm security protocols, with additional resources available through the Builder Support Program, according to the company.

Participating judges included:

Jiawei Zhu — IOSG Ventures
Lorena Zhang — Lista DAO
Deke Wilkins — Fenbushi Capital
Keith — SNZ Holding
Kun Peng — Blockchain Builders Fund; Founder, Stanford Blockchain Accelerator & BASS

Hackathon Winners

1st Place: NiR Finance
2nd Place: OmniTip
3rd Place: WingFi

Demo Night Winners

1st Place: ARST Finance
2nd Place: Delta
3rd Place: Reflex

The most recent high-profile hackathon took place in Seoul, run by XRPL Korea, which concluded with over 150 participants showcasing blockchain-fintech projects.

Recent data from Glassnode showed Bitcoin (BTC), Ether (ETH), and Solana (SOL) reflecting record high levels of their supply held at a loss. 

However, a closer examination of the locked supply, institutional holdings, and staking structures revealed that the effective liquid supply under pressure is significantly lower than the implied percentages, especially for Ether and Solana. 

Key takeaways:

A significant portion of Ether and SOL held at a loss is not liquid, with over 40% of ETH and more than 75% of SOL locked in staking, ETFs, or strategic reserves.

Bitcoin’s at-loss supply appeared high, but institutional holdings and lost BTC supply significantly reduce its true liquid float.

Positions at a loss do not reflect the actual liquid supplyBitcoin currently has 35% of its supply held at a loss, a level last seen when BTC traded near $27,000. However, even without a staking mechanism, Bitcoin’s liquid supply is far lower than the numbers suggest. The key statistics are outlined below:

BTC circulating supply: 19,953,406

BTC held by public/private companies, ETFs, and countries: 3,725,013 BTC

BTC lost forever (estimates): 3,000,000–3,800,000 BTC. This represents 15.0% to 19.0% of the total circulating supply.

Bitcoin's percentage of supply in profit is in a sharp decline. Source: GlassnodeCombined, these factors remove roughly 33% of all Bitcoin from liquid circulation. Institutional holdings, particularly ETF treasuries and corporate treasuries, are not sensitive to short-term volatility, as they operate under mandates tied to reserves, long-horizon accumulation, or index tracking. The lost BTC further reduced the supply that can react to loss-driven pressure.

Ether figures required a more nuanced interpretation. While 37% of ETH is currently held at a loss, a substantial portion of the network’s supply is locked or institutionally held:

ETH circulating supply: 120,695,601

ETH staked: 35,681,209 ETH (≈29.6%)

ETH in spot ETFs: 6.26M ETH (≈5.18%)

ETH in strategic reserves (SER): 6.36M ETH (≈5.26%)

Total ETH staked. Source: CryptoQuantIn total, over 40% of all ETH is effectively locked in staking, ETFs, or long-term institutional reserves. These categories historically do not react to short-term volatility, as institutional products (ETFs, custodial reserves) operate under policies prioritizing long-term accumulation rather than discretionary selling. As a result, the actual liquid ETH supply facing loss-driven pressure is materially smaller than the aforomentioned 37%.

Solana displayed an even sharper divergence. Although 70% of circulating SOL is held at a loss, the network has one of the highest staking ratios among major chains:

SOL circulating supply: 559,262,268

SOL staked: 411,395,790.5 SOL (73.6%)

SOL in ETFs: roughly 1% of circulating supply

Lowest SOL supply in profit in two years. Source: GlassnodeThis meant more than three-quarters of all SOL is locked in validator staking or institutional products, neither of which exhibits rapid selling behaviors. Notably, when SOL fell to $121, the supply held at a loss narrowed to 80%, a level it previously reached when the price was near $20, illustrating the metric’s sensitivity to rapid price repricing rather than structural capitulation.

Interestingly, both ETH and SOL’s supply-at-loss metrics tend to fall sharply during uptrends due to their heavy staking locks, making such spikes more reflective of price velocity than panic positioning.

Overall, across all three assets, the raw loss percentages overstate potential sell pressure. Once locked supply, institutional holdings, and permanently lost coins are accounted for, the true liquid supply at risk is significantly more contained.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

Tokyo Stock Exchange-listed Bitcoin treasury firm Metaplanet is buying more Bitcoin after securing a $130 million loan using its huge crypto holdings as collateral.

In a Tuesday notice to its shareholders, Metaplanet stated that the loan was executed on November 21 under previously approved terms, but the lender’s identity was undisclosed at the counterparty’s request. The borrowing is part of the firm’s $500 million credit facility, which allows it to raise short-term liquidity using the BTC held on Metaplanet’s balance sheet.

Metaplanet currently owns a 30,823 BTC stockpile, worth approximately $3.5 billion. The company stressed that its Bitcoin holdings are substantial enough to provide “significant collateral headroom” even during periods of jarring market volatility.

Per the notice, the $130 million loan carries a benchmark U.S. dollar rate plus a spread. The loan renews automatically daily, and the funds can be repaid at the company’s discretion.

With the fresh capital, Metaplanet’s utilization of the total $500 million credit line has increased to $230 million.

Advertisement
 

The company stated that it will utilize the loan proceeds to finance its Bitcoin acquisition spree, expand its BTC income-generation business, and share repurchases, depending on market conditions. According to Metaplanet, funds directed to its income generation business will serve as collateral to sell BTC options in order to capture premium revenue.

Metaplanet is the fourth-biggest publicly traded Bitcoin treasury company behind Michael Saylor’s Strategy, Bitcoin miner MARA, and Tether-backed Twenty One. The company temporarily halted new Bitcoin buys during the ongoing crypto market downturn but expressed that it remained firmly committed to its goal of acquiring 210,000 BTC, about 1% of the overall supply, by 2027.

Bitcoin was trading hands at around $86,978 as of press time, recovering some ground from a recent trip near $81K. The premier crypto’s price was 31% below its all-time high of $126,080 registered in October, according to crypto data provider CoinGecko. 

Pundits have previously cautioned about the perils of publicly listed firms purchasing digital assets and how it could be inherently risky. Now, the share prices of many of these companies that have amassed cryptocurrencies have plummeted amid choppy market conditions.

BNB retests key 2024 breakout level as futures interest dips and user activity grows. Traders eye $950–$1,050 if support holds.

BNB is now trading at a level that previously marked a breakout in 2024. After pulling back from its recent peak, the price is sitting right at a former resistance that’s now being tested as support.

Consequently, this area has held before and is once again in play as traders reassess short-term positioning.

BNB Returns to Channel Support
BNB is priced at $850 at press time, showing a slight 24-hour gain of over 1%, though it’s down 7% over the week. On the 2-week chart, it has tapped the upper boundary of an ascending channel, a level that capped the price action for most of 2024 and early 2025. After breaking out and reaching above $1,350, the asset has retraced to retest that same trendline.

“BNB just tapped a huge confluence level,” said CryptoPulse.

Notably, the area lines up with the previous resistance-turned-support and sits in the middle of the prior rally range. If buyers step in here, a push toward $950–$1,050 remains possible. So far, volume has not shown signs of major selling, which keeps the structure intact.

On the monthly timeframe, BNB has returned to a key trendline that has held since 2024. According to Cryptocium, BNB has not closed a monthly candle below this line with strong downside momentum.

“BNB back to the major bullish trendline,” they noted, adding that the price has respected this trend for nearly two years. As November’s monthly close approaches, traders are watching to see if bulls can defend this zone once again.

User Activity Continues to Grow
While the price action has pulled back, BNB Chain’s network activity has grown steadily in 2025. Charts shared by TCC show a rising trend in active addresses. From under a million daily users in early 2025, the chain has maintained levels above 1.5 million since July, occasionally peaking near 3.5 million.

You may also like:

Two-Thirds of BNB Supply Held by the Public, CZ Owns Less Than 1%: YZi Labs

While Ethereum Cools Off, BNB Keeps Its Heat: Data Points to Fresh Impulse Brewing

Fintech Giant Robinhood Embraces Binance Coin (BNB) and Hyperliquid (HYPE)

“BNB Chain is quietly climbing,” they posted, pointing to stronger usage despite the recent drop in price. The continued rise in network engagement may suggest underlying demand remains solid.

In addition, data from YZi Labs shows that more BNB is being stored in self-custody. Exchange balances are dropping as users move tokens to private wallets. CryptoPotato reported this shift earlier in November, noting that ownership is becoming more dispersed across the network.

Meanwhile, open interest on BNB futures is now at $1.34 billion, well below the September high near $2.8 billion. The chart shows that both the price and open interest have trended lower since that peak, pointing to less speculative activity in recent weeks.

Source: Coinglass
While the asset has found some footing in the $850–$900 range, futures interest remains muted, suggesting traders are still waiting for stronger signals.

Tags:

Falcon Finance has integrated Centrifuge's $1B JAAA token as collateral to mint USDf, marking a major step in DeFi by enabling investment‑grade structured credit and expanding real‑world asset utility onchain. Real-World Credit Becomes Active Collateral Falcon Finance has announced a major expansion of its collateral universe by integrating the tokenized asset platform Centrifuge's JAAA token.

XRP Eyes Bullish Momentum at $2.20XRP hits $2.20 with bullish momentum, as analyst Mikybull Crypto highlights rising institutional interest and strong technical signals pointing to near-term gains.

Source: Mikybull CryptoAccording to Mikybull Crypto, XRP is in a strong accumulation phase, with the $2.20 level acting as a key support. This zone reflects growing investor confidence and sets the stage for potential sharp rallies, consistent with XRP’s historical resilience at critical support points.

Technical indicators reinforce XRP’s bullish outlook. Momentum oscillators signal a shift from oversold to neutral, indicating room for upward movement, while steadily rising trading volumes suggest growing market interest. 

Therefore, analysts see this convergence as a strong catalyst for potential rallies toward higher resistance levels in the coming weeks.

XRP’s bullish case is gaining momentum beyond technical signals. The XRP Ledger is increasingly recognized as a fast, low-cost, and energy-efficient platform for cross-border payments. 

Rising adoption by financial institutions and payment providers boosts its utility and long-term demand. Mikybull Crypto notes that these network developments, combined with favorable market conditions, could spark a self-reinforcing buying cycle.

Therefore, Mikybull Crypto identifies $2.20 as a pivotal bullish level for XRP, backed by strong technical and fundamental support. Rising trading volumes and positive market developments suggest renewed upward momentum may be imminent.

XRP Supply Shock Incoming? JP Morgan Predicts $14B Inflows From New XRP & SOL ETFsBanking giant JP Morgan predicts XRP and SOL ETFs could drive $14B in new inflows. Market expert Diana calls it a potential ‘supply shock,’ signaling a pivotal boost for XRP’s price and liquidity.

ETFs have long opened the door for institutional capital, offering regulated, hassle-free exposure without managing digital wallets. JP Morgan highlights rising institutional demand for digital assets, with XRP and Solana  poised as utility-driven networks with strong adoption potential.

XRP ETFs from Canary Capital, Grayscale, and Franklin Templeton are already live. With circulating supply constrained by long-term holders and staking, an influx of institutional demand via ETFs could trigger a supply-demand imbalance. 

Diana notes this dynamic often accelerates price gains, potentially driving strong bullish momentum in the coming months if ETF adoption and investor interest continue as expected.

Solana could see a major boost from ETF exposure. Its fast, low-cost blockchain already attracts DeFi projects and NFT platforms. An SOL ETF would legitimize Solana for institutional investors, driving adoption and liquidity. JP Morgan’s $14B inflow estimate highlights the substantial capital poised to enter once ETFs launch.

Diana highlights that the proposed XRP and SOL ETFs could spark a surge in adoption and prices. With $14 billion in potential inflows, XRP may face a supply shock, presenting early investors a prime opportunity to ride the next wave of institutional interest.

ConclusionXRP at $2.20 sits at a pivotal support zone where technical strength, rising adoption, and investor optimism align. Mikybull Crypto highlights this level as a potential launchpad for renewed bullish momentum, positioning XRP as a must-watch crypto.

On the other hand, the potential launch of XRP and SOL ETFs could redefine the crypto market. With JPMorgan projecting $14B in inflows, XRP may face a supply crunch as demand outpaces availability. Beyond prices, this signals rising institutional confidence, bridging traditional finance and blockchain innovation.

Big investors reduced their MicroStrategy holdings in Q3 2025, even though Bitcoin prices stayed stable. The move signals a change in how Wall Street wants exposure to Bitcoin.
MicroStrategy became a popular Bitcoin play in 2020. Many funds could not hold Bitcoin directly, but they could buy a stock. MicroStrategy filled that gap after the company spent years loading its balance sheet with BTC.

For a long time, this idea worked. When Bitcoin hit earlier highs in 2021, MicroStrategy even traded at nearly twice the value of the Bitcoin it held per share. That premium has now faded. With more regulated options available, institutions no longer need to rely on a single company to access Bitcoin.

Wall street dumped the fuck out of Strategy in Q3 😂 pic.twitter.com/dNWFx6tvTt

— Sani | TimechainIndex.com (@SaniExp) November 14, 2025

Between Q2 and Q3, institutions cut about $5.38 billion in MicroStrategy exposure. Their holdings fell from about $36.3 billion to $30.9 billion, a drop of about 14.8 percent. This was not caused by price shocks. Bitcoin stayed near $95,000 during the quarter, and the stock held steady around $175.

The trade is not gone, but institutions are exploring new choices.

Eyes on Q4 as Bitcoin Pulls Back
The picture has shifted again in Q4. Bitcoin has retreated from its high above $125,000. If it stays under $90,000, it could expose the leverage inside MicroStrategy, including debt and dilution risk. A deeper slide toward $80,000 may trigger even larger reductions from institutions.

But if Bitcoin finds support near $100,000 or higher, MicroStrategy may keep its appeal as a leveraged Bitcoin play. A fresh rally could even bring some funds back to the stock.

💸 From Q1 to Q3, @BlackRock and @Vanguard_Group sold $5.4B in MSTR shares, while major asset managers — Capital International, Vanguard, BlackRock, and Fidelity — each reduced their holdings by $1B.

Overall, institutional positions declined from $36.32B to $30.94B.

Experts… pic.twitter.com/WbDwvaZbwR

— Mpost Media Group (@mpost_io) November 24, 2025

For now, Q4 filings will likely show mixed moves rather than a full return to past levels.

A Sign of Bitcoin’s Maturity
The shift matters because it shows how much the market has changed. Spot Bitcoin ETFs and regulated custody now let big investors hold Bitcoin directly. This makes MicroStrategy less essential and more of a tactical choice.

The company still has more than $30 billion in institutional backing, but its monopoly as a Bitcoin gateway is over.

The cut in Q3 positions does not signal an exit. It signals choice. Bitcoin exposure has matured, and institutions can now pick the route that fits their strategy. MicroStrategy remains part of that story, but no longer the center of it.

Disclaimer
The information provided by Altcoin Buzz is not financial advice. It is intended solely for educational, entertainment, and informational purposes. Any opinions or strategies shared are those of the writer/reviewers, and their risk tolerance may differ from yours. We are not liable for any losses you may incur from investments related to the information given. Bitcoin and other cryptocurrencies are high-risk assets; therefore, conduct thorough due diligence. Copyright Altcoin Buzz Pte Ltd.

Wall Street analysts forecast that new XRP and Solana exchange-traded funds will drive up the assets’ prices by attracting institutional investment. Ray Youssef, CEO of NoOnes, said that regulated products create a steady inflow channel.

The XRP and Solana ETFs have attracted just over $955 million in inflows over the past month, according to SoSoValue. This marks a sharp contrast to Bitcoin and Ethereum ETFs, which saw combined net outflows exceeding $5 billion during the same period.

Youssef predicts XRP will rise 33% and SOL 10%. Other analysts previously said they expect XRP to hit $2.50 and SOL to reach $160. The optimism comes as the broader crypto market climbed roughly 2%.

Source: DL News

Disclaimer: Crypto Economy Flash News are based on verified public and official sources. Their purpose is to provide fast, factual updates about relevant events in the crypto and blockchain ecosystem. This information does not constitute financial advice or investment recommendation.

Key Takeaways Oracle's NetSuite division hit $1 billion in Q1 FY26 revenues, growing 16% year over year.The platform integrates 100 AI agents to automate processes for mid-market businesses moving to cloud.NetSuite faces strong competition from MSFT Dynamics 365 and SAP in the crowded cloud ERP market.
Oracle’s (ORCL - Free Report) NetSuite division demonstrates sustained momentum in the mid-market enterprise segment, where businesses are transitioning from legacy on-premises systems to cloud-based platforms. The platform functions as a multi-tenant, AI-enabled system that centralizes business functions and delivers real-time insights, making it attractive for mid-sized organizations. This positioning allows NetSuite to capture demand from companies seeking modernization without the complexity of larger enterprise platforms.

The company’s NetSuite Cloud ERP division reached $1 billion in revenues during the first quarter of fiscal 2026, registering growth of 16% in USD and 15% in constant currency. This performance positions NetSuite as a significant contributor to Oracle's broader cloud momentum, which saw total cloud revenues climb 28% year over year to $7.2 billion during the quarter.

Oracle has integrated artificial intelligence capabilities across NetSuite, embedding more than 100 AI agents designed to automate processes and enhance operational efficiency. These features address a critical market shift where traditional on-premises systems cannot fully utilize advanced AI functionality, prompting businesses to migrate to cloud solutions. The integration of AI-driven automation tools strengthens NetSuite's competitive positioning as enterprises prioritize digital transformation initiatives.

The division benefits from Oracle's expanding cloud infrastructure, which provides enhanced platform reliability and geographic reach. Oracle's Remaining Performance Obligations surged 359% year over year to $455 billion, indicating robust future revenue potential. However, NetSuite primarily targets mid-sized businesses, which represents a narrower addressable market compared to Oracle's infrastructure services that serve enterprises of all sizes. NetSuite’s division also faces market saturation challenges, making it harder to maintain acceleration rates comparable to newer, high-growth cloud infrastructure offerings.

Competitive Landscape in Cloud ERPMicrosoft's (MSFT - Free Report) Dynamics 365 platform competes directly with NetSuite in the cloud ERP space, leveraging deep integration with the broader Microsoft ecosystem, including Office 365, Teams, and Azure. Microsoft's cloud applications business has demonstrated strong momentum, benefiting from its established enterprise relationships and comprehensive productivity suite. Meanwhile, SAP (SAP - Free Report) commands approximately 17% of the global ERP market as of early September 2025, surpassing Oracle's market share. SAP has accelerated its cloud transformation strategy, with cloud ERP sales and order backlog rising substantially amid growing AI adoption. Both Microsoft and SAP offer industry-specific modules and extensive partner networks, intensifying competition for mid-market and enterprise customers. The rivalry underscores the challenge Oracle faces in expanding NetSuite's market position against these established competitors with significant resources and customer bases.

ORCL’s Price Performance, Valuation & EstimatesShares of Oracle have returned 20.2% year to date against the Zacks Computer and Technology sector’s return of 6.3% and the Zacks Computer - Software industry’s growth of 25%.

ORCL’s YTD Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, ORCL stock is currently trading at a premium with a forward 12-month Price/Sales ratio of 7.64x, which is higher than the industry average of 7.36x. Oracle carries a Value Score of D.

ORCL’s Valuation
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ORCL’s fiscal 2026 earnings is pegged at $6.81 per share, marking an upward revision of one cent over the past 30 days. The earnings figure suggests 12.94% growth over the figure reported in fiscal 2025.

ORCL stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways Stepan sold SPQI in the Philippines to Masurf under a previously announced asset transfer plan.The deal lets Stepan focus on core operations while supporting customers through a new tolling agreement.The tolling arrangement aligns with Stepan's global network to ensure uninterrupted regional service.
Stepan Company (SCL - Free Report) recently announced the completion of the sale of its subsidiary Stepan Philippines Quaternaries, Inc. (“SPQI”), manufacturing assets located in Bauan, Batangas, Philippines. The assets were sold to Masurf, Inc., a subsidiary of Musim Mas Holdings Pte. Ltd.

The transaction was arranged in line with SPQI’s previously announced Asset Transfer Agreement that outlined its commitment to strategic priorities. The closing also entails SPQI entering into a tolling agreement with Masurf for the continued service of SPQI customers in Southeast Asia.

The closing of the transaction enables Stepan to sharpen the focus on core operations, positioning it for higher success in the future. The new tolling transaction will complement its existing global manufacturing network by ensuring uninterrupted service and growth opportunities for customers in Southeast Asia.

Although the terms of the transaction have not been out, the company expressed its confidence in SPQI’s thriving performance under Masurf’s stewardship and through the dedicated contributions of the Philippines team.

SCL’s shares have plunged 40.7% over the past year compared with the industry’s 25.5% decline.

Image Source: Zacks Investment Research

SCL’s Zacks Rank & Key PicksSCL currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space areKinross Gold Corporation (KGC - Free Report) , Fortuna Mining Corp. (FSM - Free Report) and Harmony Gold Mining Company Limited (HMY - Free Report) . At present, KGC sports a Zacks Rank #1 (Strong Buy), while FSM and HMY carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for KGC’s current-year earnings is pegged at $1.63 per share, indicating a rise of 139.71%. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 17.37%. KGC’s shares have risen 162.7% in the past year.

The Zacks Consensus Estimate for FSM’s current fiscal-year earnings stands at 83 cents per share.Its shares have surged 87.4% in the past year.

The Zacks Consensus Estimate for HMY’s 2026 earnings is pegged at $2.66 per share, indicating a rise of 109.45% from year-ago levels. HMY’s shares have gained 93.6% in the past year.

Egyptian President Abdel Fattah el-Sisi met Eni CEO Claudio Descalzi to review the Italian group's investments in the African country and discuss new initiatives, the energy company said on Tuesday.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Burlington Stores, Inc. (BURL) Q3 2026 Earnings Call November 25, 2025 8:30 AM EST

Company Participants

David Glick - Group Senior VP of Investor Relations & Treasurer
Michael O'Sullivan - CEO & Director
Kristin Wolfe - Executive VP & CFO

Conference Call Participants

Matthew Boss - JPMorgan Chase & Co, Research Division
Irwin Boruchow - Wells Fargo Securities, LLC, Research Division
Lorraine Maikis - BofA Securities, Research Division
John Kernan - TD Cowen, Research Division
Brooke Roach - Goldman Sachs Group, Inc., Research Division
Alexandra Straton - Morgan Stanley, Research Division
Mark Altschwager - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Operator

Hello, everyone, and welcome to Burlington Stores, Inc. Third Quarter 2025 Earnings Webcast. Please note that this call is being recorded. [Operator Instructions] I'd now like to hand the call over to Mr. David Glick, Group Senior Vice President, Investor Relations. Please go ahead.

David Glick
Group Senior VP of Investor Relations & Treasurer

Thank you, operator, and good morning, everyone. We appreciate everyone's participation in today's conference call to discuss Burlington's fiscal 2025 third quarter operating results. Our presenters today are Michael O'Sullivan, our Chief Executive Officer; and Kristin Wolfe, our EVP and Chief Financial Officer.

Before I turn the call over to Michael, I would like to inform listeners that this call may not be transcribed, recorded or broadcast without our expressed permission. A replay of the call will be available until December 2, 2025. We take no responsibility for inaccuracies that may appear in transcripts of this call by third parties. Our remarks and the Q&A that follows are copyrighted today by Burlington Stores.

Remarks made on this call concerning future expectations, events, strategies, objectives, trends or projected financial results are subject to certain risks and uncertainties. Actual results may differ materially from those that are projected in such forward-looking statements. Such risks and uncertainties

Recommended For You

NEW YORK, NY / ACCESS Newswire / November 25, 2025 / The gold market has always relied on external verification. Inspectors examined surfaces.

Key Takeaways The EU approved Dupixent for moderate-to-severe chronic spontaneous urticaria in patients 12 and older.Study A and C showed Dupixent reduced itch and hives and improved disease control versus placebo at 24 weeks.Safety findings from all LIBERTY-CUPID studies aligned with the known safety profile of Dupixent.
Sanofi (SNY - Free Report) and partner Regeneron (REGN - Free Report) announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (“CSU”) in adults and adolescents.

The targeted population for this approval includes patients aged 12 years and above with moderate-to-severe disease who have an inadequate response to histamine-1 antihistamines (H1AH) and who are naive to anti-immunoglobulin E (IgE) therapy.

Following the latest nod, Dupixent became the first targeted medicine to be approved for CSU in the European Union in over a decade. The drug is now approved for seven types of chronic, inflammatory diseases in the European Union.

CSU is an inflammatory skin condition, primarily caused by type II inflammation. This causes sudden and debilitating hives and swelling on the skin, which is mostly inadequately controlled by antihistamine treatment.

SNY’s Price PerformanceYear to date, Sanofi’s shares have gained 1.9% compared with the industry’s 16% growth.

Image Source: Zacks Investment Research

Dupixent was approved in the United States for the CSU indication in April 2025. The FDA’s approval of Dupixent for CSU marked its seventh indication, followed by another U.S. approval in June 2025 for bullous pemphigoid, reflecting the eighth indication.

Dupixent is also approved for the CSU indication in Japan.

The drug is currently approved for eight type II inflammatory diseases in the United States, including severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.

More on the Latest EU Nod for SNY/REGN's Dupixent in CSUThe European Union nod for Dupixent for the CSU indication is based on data from two late-stage studies, Study A and Study C, in the phase III LIBERTY-CUPID program, which evaluated it as an add-on therapy to standard-of-care antihistamines compared with antihistamines alone in the given patient population.

Data from the studies showed that treatment with Dupixent significantly reduced itch and hives (urticaria activity) versus placebo at 24 weeks. Treatment with Dupixent also increased the percentage of patients with well-controlled disease and complete response versus placebo at 24 weeks.

Another study in the LIBERTY-CUPID program, Study B, conducted in a different CSU patient population, provided additional safety data on treatment with Dupixent.

Importantly, safety data from Study A, Study B and Study C were similar to the known safety profile of Dupixent in its approved indications.

In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use rendered a positive opinion recommending the approval of Dupixent in the European Union for treating CSU.

Dupixent — Key Top-Line Driver for SNY & REGNDupixent is jointly marketed by Sanofi and Regeneron under a global collaboration agreement. Sanofi records global net product sales of Dupixent, while Regeneron records its share of profits or losses in connection with the global sales of the drug.

In the first nine months of 2025, Dupixent generated global product sales of €11.47 billion, which were recorded by Sanofi, representing growth of 22.7% at a constant exchange rate. Sanofi expects Dupixent to achieve around €22 billion in sales in 2030.

Regeneron recorded collaboration revenues of $4.24 billion from Sanofi during the first nine months of 2025, up 27.8% year over year.

SNY/REGN’s supplemental biologics license application seeking approval for Dupixent for treating adults and children aged six years and older with allergic fungal rhinosinusitis ("AFRS") is currently under priority review in the United States. A decision from the FDA is expected by Feb. 28, 2026.

If approved, it would be the first medicine specifically indicated for AFRS and Dupixent’s ninth U.S. approval.

SNY's Zacks Rank & Stocks to ConsiderSanofi currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Castle Biosciences (CSTL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

In the past 60 days, estimates for CorMedix’s 2025 earnings per share have increased from $1.24 to $2.87. Earnings per share estimates for 2026 have moved up from $2.09 to $2.88 during the same period. CRMD stock has surged 21.2% year to date.

CorMedix’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 27.04%.

In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from 65 cents to 23 cents. Loss per share estimates for 2026 have narrowed from $2.10 to $1.42 during the same period. CSTL stock has risen 44.5% year to date.

Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with an average surprise of 66.11%.